19 March 2024 : Original article
Long-Term Outcomes with Prolonged-Release Tacrolimus in Kidney Transplantation: A Retrospective Real-World Data Analysis
Wilfried Gwinner1ABDE*, Swapneel Anaokar2ACDE, Martin Blogg2ACDE, Birgit Hermann3ACDE, Carola del Pilar Repetur2CDE, Mario Schiffer4ABDEDOI: 10.12659/AOT.942167
Ann Transplant 2024; 29:e942167
Table 1 Baseline characteristics of patients.
| Parameter | Cohort | |||
|---|---|---|---|---|
| De novo (n=101) | Early conversion (n=12) | Late conversion (n=50) | Full analysis (N=163) | |
| Study site, n (%) | ||||
| Center 1 | 57 (56.4) | 7 (58.3) | 17 (34.0) | 81 (49.7) |
| Center 2 | 44 (43.6) | 5 (41.7) | 33 (66.0) | 82 (50.3) |
| Age, years | ||||
| Mean (SD) | 51.3 (13.7) | 53.1 (13.9) | 48.3 (13.3) | 50.5 (13.6) |
| Median (Q1–Q3) | 53.0 (42.0–63.0) | 49.0 (42.5–63.5) | 51.0 (40.0–58.0) | 52.0 (42.0–62.0) |
| Age group, n (%) | ||||
| ≥18 to <65 years | 81 (80.2) | 9 (75.0) | 45 (90.0) | 135 (82.8) |
| ≥65 years | 20 (19.8) | 3 (25.0) | 5 (10.0) | 28 (17.2) |
| Sex, n (%) | ||||
| Male | 71 (70.3) | 9 (75.0) | 37 (74.0) | 117 (71.8) |
| Female | 30 (29.7) | 3 (25.0) | 13 (26.0) | 46 (28.2) |
| Race/ethnicity, n (%) | ||||
| White/Caucasian | 55 (54.5) | 8 (66.7) | 43 (86.0) | 106 (65.0) |
| Black/African-American/Caribbean | 1 (1.0) | 1 (8.3) | 1 (2.0) | 3 (1.8) |
| Middle Eastern | 1 (1.0) | 1 (2.0) | 2 (1.2) | |
| Other | 2 (2.0) | 2 (1.2) | ||
| Not available | 42 (41.6) | 3 (25.0) | 5 (10.0) | 50 (30.7) |
| Number of previous transplants, n (%) | ||||
| 0 | 100 (99.0) | 8 (66.7) | 45 (90.0) | 153 (93.9) |
| 1 | 1 (1.0) | 4 (33.3) | 4 (8.0) | 9 (5.5) |
| 2 | 1 (2.0) | 1 (0.6) | ||
| Donor vital status | ||||
| Living | 24 (23.8) | 3 (25.0) | 28 (56.0) | 55 (33.7) |
| Deceased | 77 (76.2) | 9 (75.0) | 22 (44.0) | 108 (66.3) |
| Time from transplant to PRT conversion, months | ||||
| Mean (SD) | 0.02 (0.09) | 3.80 (1.56) | 21.02 (7.47) | 6.74 (10.43) |
| Median (Q1–Q3) | 0.00 (0.00–0.00) | 3.67 (2.40–5.05) | 21.41 (14.72–26.71) | 0.00 (0.00–12.98) |
| Time from PRT conversion to discontinuation, censoring or loss-to-follow-up, months | ||||
| Mean (SD) | 65.22 (35.84) | 55.86 (26.12) | 42.85 (16.27) | 57.67 (31.99) |
| Median (Q1–Q3) | 77.47 (35.94–89.63) | 52.24 (44.81–64.13) | 41.27 (31.97–50.89) | 55.26 (33.58–85.19) |
| Reason for conversion to PRT | ||||
| Adherence issues | 2 (4.0) | 2 (1.2) | ||
| Trough variability | 1 (1.0) | 4 (33.3) | 18 (36.0) | 23 (14.1) |
| Patient preference | 1 (1.0) | 3 (6.0) | 4 (2.5) | |
| Other clinical preference | 7 (14.0) | 7 (4.3) | ||
| Study participation | 93 (92.1) | 93 (57.1) | ||
| Not available | 6 (5.9) | 8 (66.7) | 20 (40.0) | 34 (20.9) |
| PRT – prolonged-release tacrolimus; Q – quartile; SD – standard deviation. Center 1, Universitätsklinikum Erlangen; Center 2, Medizinische Hochschule Hannover. | ||||